Efficacy and safety of Majoon Ushba oral and Marham Raal topical in tinea corporis – A randomized open-labeled active-controlled clinical trial.

• Majoon Ushba and Marham Raal are pharmacopeial preparation used effectively in tinea corporis like different skin disorders. • The ingredients have been researched and reported for diverse phytochemical characteristics and biomedical activities. • The studies reported antioxidant, antimicrobial, antifungal, anti-inflammatory, and wound-healing bioactivities. • The severity scores of clinical parameters, mycological cure, and total score were statistically significant (P ≤ 0.05). • Majoon Ushba and Marham Raal are safe and effective in reducing severity of tinea corporis and neutralizing fungal elements. Tinea Corporis is the most frequent form of dermatophytosis reported as the commonest presentation. Majoon Ushba (MU) a polyherbal preparation in a semisolid oral dosage form and Marham Raal (MR) an ointment made up of herbal and animal drugs are used for skin disorders in Unai medicine. Considering the biologically active substances with antioxidant, antimicrobial, antifungal, anti-inflammatory, and wound-healing properties of their ingredients, this study aimed to evaluate the clinical and mycological efficacy and safety of MU and MR in tinea corporis. This randomized open-labeled active-controlled clinical trial was conducted on 42 patients of tinea corporis. Patients were randomly assigned via a computer-generated list to the test group (n=21) receiving oral MU (6 gm) with topical MR and the control group (n=21) topical terbinafine hydrochloride (1%) for 40 days. The severity scores of clinical symptoms; erythema, scaling, itching, margins, and size were the primary outcome and the mycological cure (negative KOH microscopy), total score, and dermatology life quality index (DLQI) were the secondary outcomes were analyzed at baseline and at 40 days. A significant reduction was observed in clinical severity scores of erythema, scaling, and itching (P ≤ 0.05) in both groups except for margins, and size of the lesion (P ≥ 0.05). The mycological cure (P =.001) and the total score (P = 0.0002) and DLQI (P = 0.002) were statistically significant in both groups when analyzed from baseline to the end of the treatment within groups, however, the differences in these outcomes were statistically insignificant (P ≥ 0.05) on the inter-group comparison. All the safety parameters (clinical and laboratory) were in the normal range in both groups. The results demonstrated that traditional and conventional treatments were equally effective and MU and MR can be prescribed as alternative or complementary treatments for tinea corporis. [Display omitted] [ABSTRACT FROM AUTHOR]